On the public citation graph

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

0 signed · 151 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.22827openalex-snapshot
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy
inferredcites →https://doi.org/10.1007/s00280-009-1170-yopenalex-snapshot
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
inferredcites →https://doi.org/10.1007/s11912-010-0085-4openalex-snapshot
Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1016/j.ctrv.2010.01.003openalex-snapshot
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
inferredcites →https://doi.org/10.1016/j.eururo.2007.01.073openalex-snapshot
Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas
inferredcites →https://doi.org/10.1016/j.juro.2008.05.015openalex-snapshot
von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.juro.2010.06.009openalex-snapshot
VEGF Polymorphisms are Associated With an Increasing Risk of Developing Renal Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.ygyno.2009.11.011openalex-snapshot
The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
inferredcites →https://doi.org/10.1038/clpt.2010.20openalex-snapshot
Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
inferredcites →https://doi.org/10.1038/nrclinonc.2009.94openalex-snapshot
Adverse effects of anticancer agents that target the VEGF pathway
inferredcites →https://doi.org/10.1086/319501openalex-snapshot
A New Statistical Method for Haplotype Reconstruction from Population Data
inferredcites →https://doi.org/10.1086/428594openalex-snapshot
Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-Data Imputation
inferredcites →https://doi.org/10.1093/bioinformatics/bth457openalex-snapshot
Haploview: analysis and visualization of LD and haplotype maps
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1128/mcb.18.11.6178openalex-snapshot
Two Independent Internal Ribosome Entry Sites Are Involved in Translation Initiation of Vascular Endothelial Growth Factor mRNA
inferredcites →https://doi.org/10.1146/annurev.med.57.121304.131306openalex-snapshot
Angiogenesis
inferredcites →https://doi.org/10.1152/ajpregu.90502.2008openalex-snapshot
VEGF kinase inhibitors: how do they cause hypertension?
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-1655openalex-snapshot
Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-2576openalex-snapshot
The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-09-0302openalex-snapshot
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
inferredcites →https://doi.org/10.1159/000054076openalex-snapshot
A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels
inferredcites →https://doi.org/10.1161/hypertensionaha.109.129973openalex-snapshot
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
inferredcites →https://doi.org/10.1200/jco.2008.16.1612openalex-snapshot
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
inferredcites →https://doi.org/10.1200/jco.2008.19.0108openalex-snapshot
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2008.21.7679openalex-snapshot
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.3543openalex-snapshot
Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)
inferredcites →https://doi.org/10.1200/jco.2009.27.1759openalex-snapshot
Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2009.27.3037openalex-snapshot
Reply to B.I. Rini et al
inferredcites →https://doi.org/10.1586/era.09.144openalex-snapshot
Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4788499openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.2139/ssrn.4804332openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.1002/cncr.28636openalex-snapshot
Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?
inferred← citeshttps://doi.org/10.1002/cncr.28972openalex-snapshot
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
inferred← citeshttps://doi.org/10.1002/cpt.552openalex-snapshot
Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems‐Based Approaches
inferred← citeshttps://doi.org/10.1002/mc.21980openalex-snapshot
Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans
inferred← citeshttps://doi.org/10.1002/phar.1147openalex-snapshot
Antiangiogenic Therapy for Cancer: An Update
inferred← citeshttps://doi.org/10.1002/psp4.12210openalex-snapshot
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4939-1622-1_7openalex-snapshot
Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?
inferred← citeshttps://doi.org/10.1007/978-2-8178-0527-6_16openalex-snapshot
Facteurs prédictifs d’efficacité des anticorps anti-angiogéniques de la voie du VEGF
inferred← citeshttps://doi.org/10.1007/s00228-015-1935-7openalex-snapshot
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1007/s00405-015-3805-4openalex-snapshot
Minor salivary gland carcinoma: a review of 35 cases
inferred← citeshttps://doi.org/10.1007/s00432-016-2137-0openalex-snapshot
Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients
inferred← citeshttps://doi.org/10.1007/s10456-016-9534-5openalex-snapshot
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure
inferred← citeshttps://doi.org/10.1007/s11560-015-0038-xopenalex-snapshot
Hypertonie und renale thrombotische Mikroangiopathie unter anti-angiogener Tumortherapie
inferred← citeshttps://doi.org/10.1007/s11912-012-0242-zopenalex-snapshot
VEGF Inhibition, Hypertension, and Renal Toxicity
inferred← citeshttps://doi.org/10.1007/s12012-025-09980-8openalex-snapshot
Apatinib-Induced Hypertension Correlates with Improved Prognosis in Solid Tumor Patients
inferred← citeshttps://doi.org/10.1007/s12031-017-0912-2openalex-snapshot
The Importance of VEGF-KDR Signaling Pathway Genes should Not Be Ignored When the Risk of Developing Multiple Sclerosis is Taken into Consideration
inferred← citeshttps://doi.org/10.1007/s12032-013-0522-yopenalex-snapshot
Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors
inferred← citeshttps://doi.org/10.1007/s12032-017-1077-0openalex-snapshot
Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma
inferred← citeshttps://doi.org/10.1007/s12094-015-1332-9openalex-snapshot
Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma
inferred← citeshttps://doi.org/10.1007/s40264-013-0047-5openalex-snapshot
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
inferred← citeshttps://doi.org/10.1007/s40264-013-0050-xopenalex-snapshot
Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy
inferred← citeshttps://doi.org/10.1016/b978-0-12-386503-8.00006-5openalex-snapshot
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
inferred← citeshttps://doi.org/10.1016/j.bbcan.2014.11.002openalex-snapshot
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
inferred← citeshttps://doi.org/10.1016/j.clgc.2012.11.004openalex-snapshot
Beyond the Maths of Biology: Long-term Spontaneous Tumoral Regression After Sunitinib Withdrawal
inferred← citeshttps://doi.org/10.1016/j.clgc.2015.02.007openalex-snapshot
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2018.04.003openalex-snapshot
“No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!
inferred← citeshttps://doi.org/10.1016/j.ctrv.2013.11.008openalex-snapshot
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.ctrv.2014.05.003openalex-snapshot
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
inferred← citeshttps://doi.org/10.1016/j.drup.2014.10.003openalex-snapshot
Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms
inferred← citeshttps://doi.org/10.1016/j.ejcsup.2013.07.016openalex-snapshot
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejcsup.2013.07.019openalex-snapshot
Individualising treatment choices in a crowded treatment algorithm
inferred← citeshttps://doi.org/10.1016/j.eururo.2015.04.018openalex-snapshot
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.ijcard.2018.12.049openalex-snapshot
Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2017.08.012openalex-snapshot
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
inferred← citeshttps://doi.org/10.1016/j.therap.2021.11.003openalex-snapshot
Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription
inferred← citeshttps://doi.org/10.1016/j.urolonc.2013.07.010openalex-snapshot
Precision medicine for metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.urolonc.2013.08.027openalex-snapshot
Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs
inferred← citeshttps://doi.org/10.1016/j.urolonc.2013.09.011openalex-snapshot
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
inferred← citeshttps://doi.org/10.1016/j.urolonc.2013.09.015openalex-snapshot
Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization
inferred← citeshttps://doi.org/10.1016/j.urolonc.2015.11.022openalex-snapshot
Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence
inferred← citeshttps://doi.org/10.1016/s1470-2045(11)70276-5openalex-snapshot
Targeted therapy for patients with renal-cell carcinoma
inferred← citeshttps://doi.org/10.1016/s1470-2045(12)70275-9openalex-snapshot
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
inferred← citeshttps://doi.org/10.1016/s1470-2045(12)70531-4openalex-snapshot
Prognosis of renal-cell carcinoma: recognising host genetics
inferred← citeshttps://doi.org/10.1038/bjc.2012.399openalex-snapshot
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1038/bjc.2012.501openalex-snapshot
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
inferred← citeshttps://doi.org/10.1038/bjc.2014.430openalex-snapshot
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
inferred← citeshttps://doi.org/10.1038/clpt.2012.136openalex-snapshot
Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension
inferred← citeshttps://doi.org/10.1038/nrclinonc.2013.155openalex-snapshot
Molecular targets on the horizon for kidney and urothelial cancer
inferred← citeshttps://doi.org/10.1038/nrurol.2015.71openalex-snapshot
Tumour and patient factors in renal cell carcinoma—towards personalized therapy
inferred← citeshttps://doi.org/10.1038/srep20089openalex-snapshot
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma
inferred← citeshttps://doi.org/10.1038/tpj.2015.100openalex-snapshot
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1038/tpj.2016.83openalex-snapshot
Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib
inferred← citeshttps://doi.org/10.1042/bsr20170270openalex-snapshot
MicroRNA-497 suppresses renal cell carcinoma by targeting VEGFR-2 in ACHN cells
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2013.05.005openalex-snapshot
Molecular Markers to Predict Response to Therapy
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2015.09.032openalex-snapshot
Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management
inferred← citeshttps://doi.org/10.1080/14622416.2025.2579001openalex-snapshot
Genetic polymorphisms of VEGFR2 and FGFR2 genes are associated with exposure to sunitinib and cardiovascular toxicity
inferred← citeshttps://doi.org/10.1080/17425255.2020.1789589openalex-snapshot
Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated review
inferred← citeshttps://doi.org/10.1089/gtmb.2012.0222openalex-snapshot
Association of −2549 Insertion/Deletion Polymorphism of Vascular Endothelial Growth Factor with Breast Cancer in North Indian Patients
inferred← citeshttps://doi.org/10.1093/annonc/mdt219openalex-snapshot
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
inferred← citeshttps://doi.org/10.1093/jjco/hyv126openalex-snapshot
Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor
inferred← citeshttps://doi.org/10.1097/fpc.0000000000000280openalex-snapshot
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1097/md.0000000000002222openalex-snapshot
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1097/md.0000000000003413openalex-snapshot
Association of Genetic Polymorphisms on VEGFA and VEGFR2 With Risk of Coronary Heart Disease
inferred← citeshttps://doi.org/10.1097/mjt.0000000000000231openalex-snapshot
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease
inferred← citeshttps://doi.org/10.1097/mjt.0000000000000331openalex-snapshot
Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients
inferred← citeshttps://doi.org/10.1111/cas.14609openalex-snapshot
Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy
inferred← citeshttps://doi.org/10.1111/iju.12858openalex-snapshot
Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1111/iju.13956openalex-snapshot
Current status of prognostic factors in patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1136/esmoopen-2015-000013openalex-snapshot
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-1351openalex-snapshot
Molecular Biomarkers in Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1159/000438615openalex-snapshot
Aquaporin-3 Inhibition Reduces the Growth of NSCLC Cells Induced by Hypoxia
inferred← citeshttps://doi.org/10.1161/hypertensionaha.112.196774openalex-snapshot
Management of Antiangiogenic Therapy-Induced Hypertension
inferred← citeshttps://doi.org/10.1177/23993693211001374openalex-snapshot
Onco-hypertension: Overview of hypertension with anti-cancer agents
inferred← citeshttps://doi.org/10.1186/1471-2407-12-107openalex-snapshot
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
inferred← citeshttps://doi.org/10.1186/gm295openalex-snapshot
Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
inferred← citeshttps://doi.org/10.1186/s13045-018-0617-1openalex-snapshot
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
inferred← citeshttps://doi.org/10.1200/jco.2012.42.7260openalex-snapshot
Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study)
inferred← citeshttps://doi.org/10.1253/circrep.cr-26-0054openalex-snapshot
Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib
inferred← citeshttps://doi.org/10.1371/journal.pone.0076386openalex-snapshot
Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1371/journal.pone.0134102openalex-snapshot
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1371/journal.pone.0145410openalex-snapshot
Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1371/journal.pone.0148177openalex-snapshot
Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
inferred← citeshttps://doi.org/10.14694/edbook_am.2012.32.25openalex-snapshot
The Evolving Landscape of Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1517/13543784.2013.816282openalex-snapshot
Targeting tyrosine-kinases in ovarian cancer
inferred← citeshttps://doi.org/10.1517/17425255.2012.656845openalex-snapshot
Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy
inferred← citeshttps://doi.org/10.1586/14737159.2015.1032261openalex-snapshot
Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges
inferred← citeshttps://doi.org/10.1586/14737159.2016.1148601openalex-snapshot
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
inferred← citeshttps://doi.org/10.1634/theoncologist.2011-0163openalex-snapshot
Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs
inferred← citeshttps://doi.org/10.1684/bdc.2014.1935openalex-snapshot
[Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].
inferred← citeshttps://doi.org/10.18632/oncotarget.13597openalex-snapshot
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
inferred← citeshttps://doi.org/10.18632/oncotarget.17833openalex-snapshot
Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: a meta-analysis
inferred← citeshttps://doi.org/10.18632/oncotarget.19924openalex-snapshot
Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.18632/oncotarget.26380openalex-snapshot
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
inferred← citeshttps://doi.org/10.18632/oncotarget.9229openalex-snapshot
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2020.0187openalex-snapshot
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.2147/ott.s197923openalex-snapshot
Sunitinib-and-Chinese herbal medicine-based systematic treatment clinically cured a patient with multiple metastatic primary clear cell carcinoma of the liver: a case report
inferred← citeshttps://doi.org/10.2147/ott.s41828openalex-snapshot
Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
inferred← citeshttps://doi.org/10.2174/1381612827666211006145141openalex-snapshot
Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
inferred← citeshttps://doi.org/10.2174/156800912802429265openalex-snapshot
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.2217/bmm.12.19openalex-snapshot
Can Knowledge of Germline Markers of Toxicity Optimize Dosing and Efficacy of Cancer Therapy?
inferred← citeshttps://doi.org/10.2217/fon.13.58openalex-snapshot
Metastatic Renal Cell Carcinoma: How to Make the Best Sequencing Decision After Withdrawal for Intolerance to a Tyrosine Kinase Inhibitor
inferred← citeshttps://doi.org/10.2217/fon.14.120openalex-snapshot
Tivozanib for the Treatment of Renal Cell Carcinoma: Results and Implications of the TIVO-1 Trial
inferred← citeshttps://doi.org/10.2217/pgs.12.142openalex-snapshot
Constitutional Genetic Variants as Predictors of Antiangiogenic Therapy Outcome in Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.2217/pgs.14.136openalex-snapshot
Impact of VEGF Gene Polymorphisms in Elderly Cancer Patients: Clinical Outcome and Toxicity
inferred← citeshttps://doi.org/10.3109/21681805.2015.1021833openalex-snapshot
Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma
inferred← citeshttps://doi.org/10.33667/2078-5631-2022-17-30-41openalex-snapshot
Anti-cancer agents and drug-induced hypertension
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1488853openalex-snapshot
Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models
inferred← citeshttps://doi.org/10.3389/fonc.2019.01400openalex-snapshot
Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
inferred← citeshttps://doi.org/10.3389/fphar.2021.641075openalex-snapshot
Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers14122838openalex-snapshot
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
inferred← citeshttps://doi.org/10.3390/cancers14246167openalex-snapshot
Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
inferred← citeshttps://doi.org/10.3390/cancers15061851openalex-snapshot
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
inferred← citeshttps://doi.org/10.3390/diagnostics11040640openalex-snapshot
Nephrotoxicity of Anti-Angiogenic Therapies
inferred← citeshttps://doi.org/10.3390/ijms17122073openalex-snapshot
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
inferred← citeshttps://doi.org/10.3390/jcm9051594openalex-snapshot
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
inferred← citeshttps://doi.org/10.3978/j.issn.2072-1439.2012.10.11openalex-snapshot
Anti-angiogenic treatments in advanced NSCLC: back to the drawing board.
inferred← citeshttps://doi.org/10.3978/j.issn.2223-4683.2012.09.01openalex-snapshot
New prognostic models in metastatic renal cancer.
inferred← citeshttps://doi.org/10.3978/j.issn.2223-4683.2012.10.01openalex-snapshot
Biomarkers for tyrosine kinase inhibitors in renal cell cancer.
inferred← citeshttps://doi.org/10.4103/0019-509x.180824openalex-snapshot
Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma
inferred← citeshttps://doi.org/10.5334/ojb.aeopenalex-snapshot
Public Oncologic Serum Biobank
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.